companydata.dkNovo Nordisk Invest 4 A/S: Financial statements 2013
CVR: 31853923
Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2013. In 2013, the company reported revenue of DKK 181,767,000 and a net result of DKK -214,000. The profit margin was -0.1%. Equity amounted to DKK 5,681,000. The solvency ratio was 8.5%.
- Revenue
- 181,767,000 kr.
- Profit/Loss
- -214,000 kr.
- Equity
- 5,681,000 kr.
- Total Assets
- 66,781,000 kr.
Find more companies like Novo Nordisk Invest 4 A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2013
Novo Nordisk Invest 4 A/S has published its annual report for 2012.
As of March 22, 2013, Nana Folmann Hempler has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Majken Borup Linnemann Jensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Kristine Færch has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Bo Ahrén has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Dorthe Tecza has left the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Peder Rasmussen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Niels Borregaard has left the board of directors of Novo Nordisk Invest 4 A/S.
About Novo Nordisk Invest 4 A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.